Puma Biotechnology Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Puma Biotech (PBYI) Tops Q3 EPS by 59c, Revenues Miss
November 6, 2019 6:03 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q3 EPS of ($0.12), $0.59 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $60.4 million.
In the third quarter of 2019 we were pleased to report that our supplemental New Drug Application for neratinib for the treatment of third-line HER2-positive metastatic breast cancer was accepted by the... More
